INTRODUCTION

Initial studies have focused on CT findings and its diagnostic accuracy in COVID-19. CT has been demonstrated to be highly sensitive during its use as a first-line investigation for COVID-19 in mainland China where the outbreak commenced, but there are limited studies that assess the diagnostic accuracy of CXRs in COVID-19. To determine the accuracy of CXR diagnosis of COVID-19 compared with PCR in patients presenting with a clinical suspicion of COVID-19.

Methods and materials: The CXR reports of 569 consecutive patients with a clinical suspicion of COVID-19 were reviewed, blinded to the PCR result and classified into the following categories: normal, indeterminate for COVID-19, classic/probable COVID-19, non-COVID-19 pathology, and not specified. Severity reporting and reporter expertise were documented. The subset of this cohort that had CXR and PCR within 3 days of each other were included for further analysis for diagnostic accuracy.

Results: Classic/probable COVID-19 was reported in 29% (166/569) of the initial cohort. 67% had PCR tests. 344 patients had CXR and PCR within 3 days of each other. Compared to PCR as the reference test, initial CXR had a 61% sensitivity and 76% specificity in the diagnosis of COVID-19.

Conclusion: Initial CXR is useful as a triage tool with a sensitivity of 61% and specificity of 76% in the diagnosis of COVID-19 in a hospital setting.

Advances in knowledge: Diagnostic accuracy does not differ significantly between specialist thoracic radiologists and general radiologists including trainees following training. There was a 40% prevalence of PCR positive disease in the cohort of patients having CXR and PCR within 3 days of each other. Classic/probable COVID-19 was reported in 18% of total cohort of patients presenting with clinical suspicion of COVID-19 (n = 569). Initial CXR is useful as a triage tool with a sensitivity of 61% and specificity of 76% in the diagnosis of COVID-19 in a hospital setting.
The British Society of Thoracic Imaging (BSTI) have advised the use of the CXR as the first-line imaging investigation for patients presenting during the pandemic with a clinical suspicion of COVID-19 infection, with “immediate/hot” reporting of the CXR to differentiate classic/probable COVID-19 infection from non-COVID-19 infection. This result can be used to assist in the triage of patients awaiting diagnostic PCR tests. CT was to be reserved for cases with either diagnostic uncertainty or for patients that are significantly more hypoxic than would be expected from the CXR appearances. As an additional consideration, CT scanners must be decontaminated after patients with confirmed or suspected COVID-19 to reduce the infection risk to other acutely unwell or cancer patients. This takes time and has significant implications for service provision in the context of an already stretched CT capacity, further limiting the role that CT can play in the diagnosis of COVID-19 in many healthcare settings including the UK National Health Service.

We reviewed the accuracy of CXR diagnosis and severity scoring of COVID-19 compared with PCR in patients presenting with a clinical suspicion of COVID-19. Additionally, as the CXRs are to be “hot” reported 24 h per day, we compared the diagnostic accuracy of thoracic radiologists to general radiologists including those in training, as they would also be “hot” reporting the chest radiographs.

In order to ensure that all reporters were adequately trained on reporting COVID-19 CXRs, a departmental tutorial took place and a dedicated training set of CXRs with notes and references was made available for all reporters.

METHODS AND MATERIALS
We performed an electronic search of the Radiology Information System (RIS) to identify all consecutive CXRs between 1 February and 6 April 2020 performed due to clinical suspicion of COVID-19. The comprehensive list of COVID-19 related terms is provided (Supplementary Table 1). Exclusion of follow-up imaging, those without a clinical suspicion of COVID-19 (according to the CXR request and electronic patient record) and children resulted in a total of 569 patients for inclusion in the study (see investigation flowchart, Figure 1). Symptomatic data were collected (HC, AL, SAP, SP, IS, RS) from the electronic patient record. CXR reports were reviewed, blinded to the PCR result (MT, AM), and classified into the following categories: normal, indeterminate for COVID-19, classic/probable COVID-19, non-COVID-19 pathology and not specified (Figure 2 for example images). Severity reporting into mild, moderate and severe or whether not specified, and reporter expertise (thoracic radiologists vs general radiologist including trainees) were documented. The project received institutional approval as a service improvement audit and informed consent was waived.

PCR testing
At this point, early in the pandemic, the PCR testing strategy was to test only those who had a clinical suspicion of COVID-19, who also had a severe enough syndrome requiring hospital admission. Those with suspected mild disease were discharged without PCR testing. A combined nose and throat swab were taken using a flocked swab and transported to the laboratory in viral transport medium. Guidance on taking a good quality swab was provided through the hospital website. RNA extraction was carried out on the Qiagen Symphony platform and amplification of SARS-CoV-2 RNA was carried out on the Qiagen Rotorgene using the RdRp assay.

RESULTS
Patient and investigation characteristics
569 consecutive patients were identified from the clinical history within the CXR requests and subsequently the electronic patient record, as having a clinical suspicion of COVID-19. The median age was 61 years (range 17–104 years), with a male:female ratio of 51:49. Of the 569 patients, thoracic radiologists reported 28%. 67% (382/569) had PCR tests, with 18% (104/569) having multiple tests (Table 1). Median turnaround time of PCR test from collection to result was 27 h compared to 7 h for the CXR.
The most common symptoms were cough, fever and shortness of breath.

**CXR reporting**

Classic/probable COVID-19 was reported in 29% (166/569) of the initial cohort (Figure 3). Of the 60% (99/166) that reported severity, 31 were mild, 52 moderate and 16 severe (Figure 4).

**PCR testing**

PCR testing per report category is shown in Figure 5. PCR testing was conducted in 84% (139/166) of those with CXRs reported as classic/probable COVID-19 and was positive in 60% of cases (83/139), while in patient with CXRs reported as normal PCR testing took place in 52% (144/279) and was positive in only 17% (24/144).

**CXR correlation with PCR**

In the subset of patients with PCR testing within 3 days of CXR, classic/probable COVID was reported in 38% (132/344) of cases, and there was a 40% (137/344) prevalence of PCR positive disease. 4% (24/569) of patients became positive after the initial swab.

When compared to PCR as the reference standard, CXR had a 61% sensitivity (95% CI 52–69%) and a specificity of 76% (95% CI 70–82%) (Tables 2 and 3).
26% (87/344) cases with paired PCR result were reported by thoracic radiologists. The chest radiologists’ sensitivity of 63% (95% CI 44–79%) and specificity 76% (95% CI 63–87%) did not differ from non-thoracic radiologists 60% (95% CI 50–69%) and specificity of 76% (69–83%) by Fisher’s exact test. The addition of the indeterminate category resulted in a slight increase in sensitivity and a slight decrease in specificity as would be expected (Tables 4 and 5); however, this was not found to be statistically significant, by Fisher’s exact test.

18% (104/569) had two or more PCR tests. Out of 81 patients who had more than one PCR, but whose initial PCR test was negative and within 3 days of their CXR, 24 subsequently tested positive. Nine of these patients had a diagnosis of classic/probable COVID-19 on initial CXR, a median of 6.1 days prior to the positive PCR report.

**DISCUSSION**

Our study demonstrates the diagnostic accuracy of initial CXR compared to PCR in a SARS-CoV-2 cohort of otherwise unselected patients presenting acutely to the emergency department. By including a consecutive sample of all patients being investigated for COVID-19 with a CXR, our results are likely to be generalisable to the presenting case load in other similar settings.

UK testing strategy at this point in the pandemic only included patients with severe enough illness to require admission to hospital, the cohort with paired CXR and SARS-CoV-2 PCR will therefore be biased towards those with more severe disease. Another important consideration is that the sensitivity of both PCR and CXR is highly dependent on the timing within the disease course. To minimise bias arising from test timing, we limited our analysis to cases in which CXR and PCR had been performed within 3 days.

An important limitation of the study is the use of upper respiratory tract SARS-CoV-2 PCR as the reference standard against which to compare the diagnostic performance of CXR. The sensitivity of PCR is affected by the timing of sampling, the quality sample taken as well as the performance of the assay used. Published studies suggest upper respiratory tract PCR has a sensitivity of 70–80% \(^{3,4}\) against a composite reference standard incorporating clinical, radiological and microbiology data. We chose not to use a composite reference standard including a clinical data and/or CT as a consensus definition is lacking. However, the imperfect sensitivity of PCR does mean that some PCR negative cases may have been COVID-19 cases. Our estimate of the

| Statistic                      | Value | 95% CI |
|-------------------------------|-------|--------|
| Sensitivity                   | 61%   | 52–69% |
| Specificity                   | 76%   | 70–82% |
| Positive Likelihood Ratio     | 2.6   | 1.9–3.4 |
| Negative Likelihood Ratio     | 0.52  | 0.41–0.64 |
| Disease prevalence            | 40%   | 35–45% |
| Positive Predictive Value     | 63%   | 54–71% |
| Negative Predictive Value     | 75%   | 68–80% |

| Statistic                      | Value | 95% CI |
|-------------------------------|-------|--------|
| Sensitivity                   | 61%   | 52–69% |
| Specificity                   | 76%   | 70–82% |
| Positive Likelihood Ratio     | 2.6   | 1.9–3.4 |
| Negative Likelihood Ratio     | 0.52  | 0.41–0.64 |
| Disease prevalence            | 40%   | 35–45% |
| Positive Predictive Value     | 63%   | 54–71% |
| Negative Predictive Value     | 75%   | 68–80% |

| 2 × 2 table of CXR (classic/probable COVID or indeterminate) vs PCR |
|-------------------------------------------------------------------|
| **CXR positive (classic/probable or indeterminate for COVID)**  |
| PCR positive                      | 90    |
| PCR negative                     | 62    |
| **CXR negative**                 |
| PCR positive                      | 47    |
| PCR negative                     | 145   |
specification of CXR should therefore be treated with caution and may be an underestimate.

According to reporting guidelines for our institution, use of the indeterminate category for reporting films with a clinical suspicion of COVID-19 was limited to reduce the burden of further CT imaging and allow more decisive triage. We have demonstrated in further analysis that addition of the indeterminate report category to equate to CXR diagnosis of COVID-19 increases sensitivity but reduces specificity.

An overall sensitivity of 61% for the CXR is comparable to the report by Wong et al,8 which only included patients with PCR positive COVID-19 disease. The sensitivity is higher than reported by Weinstock et al,9 who reported that 58.3% of PCR positive patients presenting with mild symptoms to a non-emergency department in New York City had a normal CXR, a setting with a markedly different testing strategy.

Importantly, because the CXR appearances of COVID-19 are now relatively well reported, it is possible to produce training sets for general radiologists and those in training that enable them to practice for this diagnosis to the same standard as specialist radiologists. It may also be possible to train emergency doctors to the same level of competence.

In summary, we have shown that among patients presenting to an emergency department, CXR is 60% sensitive and 76% specific compared to upper respiratory tract SARS-CoV-2 PCR; and that once trained, all radiologists may report the CXR with similar levels of accuracy.

ACKNOWLEDGEMENTS
Hannah Chase, Archie Lodge, Sai Arathi Parepalli, Sarah Peters, Ishita Sharma, Raghav Sudarshan – Oxford University Medical Students. Individual analysis of electronic patient record of each patient

| Statistic                      | Value | 95% CI    |
|-------------------------------|-------|-----------|
| Sensitivity                   | 66%   | 57–74%    |
| Specificity                   | 70%   | 63–76%    |
| Positive Likelihood Ratio     | 2.2   | 1.7–2.8   |
| Negative Likelihood Ratio     | 0.49  | 0.38–0.63 |
| Disease prevalence            | 40%   | 35–45%    |
| Positive Predictive Value     | 59%   | 51–67%    |
| Negative Predictive Value     | 76%   | 69–81%    |

REFERENCES
1. Shi H et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet. Infect. Dis 2020; 3099: 1–10.
2. Y Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur. Radiol 2020; 2019: 1–9.
3. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology 2020; 296: E115–7. doi: https://doi.org/10.1148/radiol.2020200432
4. Tao AI MD, Yang Z, Hou H. Correlation of chest CT and RT-PCR testing in coronavirus disease. 2014; 80: 1–9.
5. Wu J et al. Chest CT findings in patients with corona virus disease 2019 and its relationship with clinical features. Invest. Radiol 2020; 1.
6. Hao W, Li M. Clinical diagnostic value of CT imaging in COVID-19 with multiple negative RT-PCR testing. Travel Med Infect Dis 2020; 34: 101627. doi: https://doi.org/10.1016/j.tmaid.2020.101627
7. Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Invest Radiol 2020; 55: 327–31. doi: https://doi.org/10.1097/RLI.0000000000000672
8. Wong HY F et al. Frequency and distribution of chest radiographic findings in COVID-19 positive patients. Radiology 2019; 201160.
9. Weinstock MB et al. Chest X-ray findings in 636 ambulatory patients with COVID-19 presenting to an urgent care center: a normal chest X-ray is no guarantee. J. Urgent Care Med.
10. Jacobi A, Chung M, Bernheim A, Eber C. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information 2020;
11. Mann DC. BSTI NHSE COVID-19 RADIOLOGY DECISION SUPPORT TOOL. Available from: https://www.bsti.org.uk/standards-clinical-guidelines/clinical-guidelines/bsti-nhse-covid-19-radiology-decision-support-tool/.
12. Chua F, Armstrong-James D, Desai SR, Barnett J, Kouranos V, Kon OM, et al. The role of CT in case ascertainment and management of COVID-19 pneumonia in the UK: insights from high-incidence regions. Lancet Respir Med 2020; 8: 438–40. doi: https://doi.org/10.1016/S2213-2600(20)30132-6
13. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance 2020; 25: 1–825. doi: https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045